1. Definitions and Core Concepts

Pharmacovigilance (PV) is defined by the World Health Organization (WHO) as ‘the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.’ This definition, while succinct, encompasses a vast domain of scientific, regulatory, and public health activity that touches every stage of a medicine’s lifecycle, from the moment it enters clinical trials through to decades of post-market use.

Several closely related terms are essential to understand:

• Adverse Drug Reaction (ADR): A response to a medicinal product which is noxious and unintended, and which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function. This definition, from the EU Directive 2001/83/EC and adopted broadly, includes reactions from medication errors, misuse, abuse, and off-label use.
• Adverse Event (AE): Any untoward medical occurrence in a patient administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An adverse event is a broader term that captures all occurrences, regardless of causality.
• Signal: Reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Signals may come from spontaneous reports, clinical trials, literature, or digital data sources.
• Benefit-Risk Assessment: The formal evaluation of the therapeutic benefits of a medicine against its risks (ADRs, interactions, contraindications). PV contributes ongoing data to this continuously evolving assessment.
• Medication Error: Any preventable event that may cause or lead to inappropriate medication use or patient harm. This is an increasingly important domain within modern pharmacovigilance.

2. Historical Development of Pharmacovigilance

The formal discipline of pharmacovigilance emerged from tragedy. Several key historical events shaped its development:

2.1 Pre-thalidomide era

Prior to the 1960s, systematic post-market drug safety monitoring was virtually non-existent. Drug regulation focused primarily on efficacy and quality. Adverse reactions were generally managed on an ad hoc basis, often only after significant harm had accumulated in the population. The sulfanilamide disaster of 1937, in which over 100 Americans died from a diethylene glycol-based preparation of the antibiotic, triggered the Food, Drug, and Cosmetic Act of 1938 in the United States, introducing pre-market safety evidence requirements. However, systematic post-market surveillance remained absent.

2.2 The thalidomide disaster (1957–1962)

The thalidomide catastrophe is universally regarded as the founding event of pharmacovigilance. Thalidomide, marketed as a sedative and anti-nausea medication for pregnant women, caused severe limb malformations (phocomelia) and other birth defects in an estimated 10,000 to 20,000 children worldwide between 1957 and 1962. The drug had been approved in West Germany and widely distributed in Europe, Australia, Canada, and Africa, though notably rejected by the US FDA due to inadequate safety data.

The thalidomide disaster exposed the catastrophic inadequacy of pre-market testing in detecting teratogenic effects. It directly catalysed the establishment of organised post-marketing surveillance systems. In 1968, WHO launched the Programme for International Drug Monitoring (PIDM), initially as a pilot with 10 countries. This programme remains the backbone of global pharmacovigilance coordination today.

2.3 Post-thalidomide milestones

• 1968: WHO Programme for International Drug Monitoring established
• 1978: Uppsala Monitoring Centre (UMC) established in Sweden as the WHO Collaborating Centre
• 1994: International Conference on Harmonisation (ICH) guidelines begin to formalise safety reporting standards
• 2000: WHO Policy Perspectives on Medicines introduces PV as a public health priority
• 2002: WHO publication ‘The Importance of Pharmacovigilance’ articulates the modern framework
• 2010: WHO Minimum Requirements for National Pharmacovigilance Systems published
• 2013: WHO Global Benchmarking Tool for regulatory systems integrates PV assessment
• 2015: ICH E2B(R3) guideline standardises electronic transmission of individual case safety reports
• 2019: WHO Good Pharmacovigilance Practices (GVP) guidelines updated

3. Scope of Modern Pharmacovigilance

Contemporary pharmacovigilance extends well beyond the traditional focus on adverse drug reactions reported by healthcare professionals. Its modern scope includes:

• Spontaneous ADR reporting from healthcare providers and patients
• Systematic pharmacoepidemiological studies (cohort, case-control, prescription event monitoring)
• Targeted follow-up studies (registries, PASS-post-authorisation safety studies)
• Signal detection and management
• Risk communication and risk minimisation measures
• Medication error monitoring and prevention
• Herbal, traditional, and complementary medicine safety
• Vaccine safety surveillance (AEFI monitoring)
• Counterfeit and substandard medicine detection
• Medicines use in special populations (children, pregnant women, elderly)
• Digital pharmacovigilance using real-world evidence, electronic health records, social media

4. Objectives of Pharmacovigilance

The WHO defines the core objectives of pharmacovigilance as:

1. Improving patient care and safety in relation to medicine use, and in all medical and paramedical interventions
2. Improving public health and safety in relation to medicine use
3. Contributing to the assessment of benefit, harm, effectiveness, and risk of medicines, encouraging their safe, rational, and more effective use
4. Promoting understanding, education, and clinical training in pharmacovigilance, and its effective communication to the public